Quick Answer
CytomX Therapeutics, Inc. reported Net Income Loss of -$17.37 million for the year ending 2025.
- CytomX Therapeutics, Inc. showed a decrease of -154.5% in Net Income Loss from 2024 to 2025.
- This data is from CytomX Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: -$14.18 million | Q3 2016: -$14.66 million | Q4 2016: -$14.03 million | Q1 2017: -$8.26 million | Q2 2017: -$25.22 million | Q3 2017: -$10.25 million | Q4 2017: $621.0 thousand | Q1 2018: -$15.49 million | Q2 2018: -$13.45 million | Q3 2018: -$23.43 million | Q4 2018: -$32.23 million | Q1 2019: -$14.12 million | Q2 2019: -$28.96 million | Q3 2019: -$23.70 million | Q4 2019: -$35.46 million | Q1 2020: $12.21 million | Q2 2020: -$15.68 million | Q3 2020: -$14.71 million | Q1 2021: -$15.55 million | Q2 2021: -$19.24 million | Q3 2021: -$22.58 million | Q1 2022: -$31.98 million | Q2 2022: -$29.50 million | Q3 2022: -$29.06 million | Q1 2023: -$3.31 million | Q2 2023: -$1.09 million | Q3 2023: $2.99 million | Q1 2024: $13.79 million | Q2 2024: -$6.53 million | Q3 2024: $5.74 million | Q1 2025: $23.53 million | Q2 2025: -$154.0 thousand | Q3 2025: -$14.23 million.
- Over the full 13 years of available data (2013 to 2025), CytomX Therapeutics, Inc.'s Net Income Loss has declined by 14.7%.
- Historical annual values: Fiscal year 2025: -$17.37 million | Fiscal year 2024: $31.87 million | Fiscal year 2023: -$569.0 thousand | Fiscal year 2022: -$99.32 million | Fiscal year 2021: -$115.87 million | Fiscal year 2020: -$32.89 million | Fiscal year 2019: -$102.24 million | Fiscal year 2018: -$84.60 million | Fiscal year 2017: -$43.10 million | Fiscal year 2016: -$58.90 million | Fiscal year 2015: -$35.37 million | Fiscal year 2014: -$30.31 million | Fiscal year 2013: -$15.14 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: